Background {#Sec1}
==========

Sarcomas are a heterogeneous group of rare malignant tumors derived from primitive mesenchymal cells. These tumors arise from muscle, connective tissue, supportive tissue and vascular tissue, and more than 80 histologic subtypes are included in the 2013 World Health Organization (WHO) Classification of Tumors of Soft Tissue and Bone \[[@CR1]\]. In addition to having a multiple and complex histology, these tumors can occur in almost any anatomic site. In spite of these facts, sarcomas account for less than 1% of all adult cancers and for about 20% of all malignant solid tumors in children, adolescents and young adults \[[@CR2]\].

From an epidemiological point of view, the lack of a unified method of reporting sarcomas has led to considerable variations in the reported incidence and time trends Sarcomas are sometimes mistaken for carcinomas of the same organ, and can involve a variety of localizations. As a consequence, 30 % of sarcomas are misclassified at initial diagnosis \[[@CR3]\]. In addition, sarcomas encompass a wide variety of histological and molecular subtypes and are categorized in rapidly evolving phenotypic and molecular subgroup classification schemas now used for sarcoma diagnosis, which has a growing impact on the management of patients \[[@CR4]\]. Furthermore, innovation in immune-histochemistry and molecular biology techniques in the last three decades has led to major changes in the diagnosis and classification of sarcoma subtypes.

Currently, data for sarcomas in the French population are provided by the reference networks for sarcomas that collect and manage cases of soft tissue, bone and visceral sarcomas. Reference networks propose a systematic second histologic review by expert pathologists \[[@CR5]--[@CR7]\]. A few French studies carried out by these reference networks provided world age-standardized incidence rates of 4.8 and 3.3 per 100,000 inhabitants per year for all sarcomas and soft-tissue sarcomas (STS) respectively \[[@CR8], [@CR9]\]. However, data from these reference networks based on the voluntary participation are not totally exhaustive.

Besides reference networks, cancer surveillance information is coming from the French Network of population-based cancer registries that exhaustively collects all newly diagnosed and confirmed cancer cases within geographical areas in France \[[@CR10]\]. The exhaustive collection of sarcoma cases from population-based cancer registries and the systematic second review of diagnosis from reference centers offer an optimal framework to study the incidence and time trends of sarcomas in France. The incidence trends have never been studied in France and the results from other countries are divergent \[[@CR11]\]. We undertook this study to describe sarcoma entity according to anatomic sites, histologic subtypes and genetic groups based on guidelines developed by sarcoma specialists.

Methods {#Sec2}
=======

Data sources {#Sec3}
------------

Cases included in this study were children and adults with sarcoma diagnosed between January 1, 2000 and December 31, 2013, and living in one of the administrative areas covered by a population-based cancer registry of the French Network (details in online supplementary material). The French sarcoma pathological reference network (RRePS) and the French reference Network for bone sarcoma and rare bone tumors (RESOS) propose a systematic second histologic review and confirmation for all diagnoses of sarcomas across France \[[@CR6]\].

Data collection and classification {#Sec4}
----------------------------------

The following data were collected for each case: general demographic characteristics of the patients (age, sex, and residence area), the date of diagnosis, the anatomical site, and the histology of the tumor according to the International Classification of Diseases for Oncology, third edition (ICD-O-3) (12).

This study included intermediate (only with a "/3" behavior) and malignant sarcomas presenting morphologic criteria described in the 2013 WHO Classification of Tumors of Soft Tissue and Bone (fourth edition), regardless of the anatomic site \[[@CR1]\]. This recent classification includes histologic updates not defined in ICD-O-3 and new terms, synonyms, morphology and behavior codes. For this reason, and whenever possible, cases were reclassified according to the updated version. The alignments from ICD-O-3 to the 2013 WHO standard classification of tumors have been validated by a panel of sarcoma specialists (clinical and pathological experts) from sarcoma Networks (NP, JMC and IRC).

Certain alignments could not be performed: ten morphological terms not described in this updated classification (e.g. sarcoma NOS, periosteal fibrosarcoma, fascial fibrosarcoma ...) have been maintained for analyses. Conversely, well differentiated liposarcoma and chondroblastoma have been changed from malignant to borderline diseases. In the same way, behaviors for dermatofibrosarcoma protuberans and pigmented dermatofibrosarcoma protuberans have been also changed from malignant to borderline with henceforth, only fibrosarcomatous dermatofibrosarcoma protuberans which is coded as malignant behavior. In our analyses, we have made the choice to keep all dermatofibrosarcomas. Indeed, we do not have the possibility to differentiate if this is a dermatofibrosarcoma borderline or malignant. Besides, endometrial stromal sarcoma NOS (89303), low grade endometrial stromal sarcoma (89313) and stromal sarcoma (89353) not described in the WHO 2013 have been also included. Additional details on the list and choice of classification systems are provided in the online supporting material (see Additional File [1](#MOESM1){ref-type="media"}).

This classification also provides new genetic and molecular data for each histologic entity allowing a better characterization of sarcomas. The same group of experts were consulted with the aim of proposing the optimal classification system for sarcomas based on the genetic profile. Two main distinct genetic groups were defined: (i) sarcomas defined with simple genetics based on recurrent translocations (e.g. Ewing sarcoma, myxoïd liposarcoma), activating or inactivating mutations (e.g epithelioid sarcoma, gastrointestinal stromal tumor), *MDM2* amplification (e.g. dedifferentiated liposarcoma, low-grade central osteosarcoma); and (ii) sarcomas with complex genomic profiles (e.g. angiosarcoma, leiomyosarcoma). Another group was defined for miscellaneous and undefined alterations. The list of histology codes according to their genetic groups is presented in the supplementary material.

This study is based on data from cancer registries gathered in the French network of cancer registries and a representative of each registry was involved in the study and approved the use of its data All French registries received an authorization to collect patient data from the data protection authority (Commission Nationale de l'Informatique et des Libertés). Ethics approval and consent to participate were not required for this study which is an observational research without direct contact with patient.

Statistical analyses {#Sec5}
--------------------

Two datasets were used: i) the first one was used to estimate the incidence of patients diagnosed during the 2010--13 period and that included data from 19 registries; and ii) the second one was used to examine trends in the incidence from 2000 to 2013 in only 11 registries for which data were available over the entire studied period. Incidence rates were presented per 100,000 person-years.

The incidence of sarcomas was described according to 1) the anatomic group (i.e. soft-tissue, bone, gastro-intestinal, skin, female genital organs, other viscera and other sites), and to 2) histologic and 3) genetic groups based on guidelines developed by sarcoma specialists (see Additional File [1](#MOESM1){ref-type="media"}).

Age-standardized incidence rates (ASR) were estimated using direct standardization and were calculated using the population data for each age group and year supplied by the National Institute of Statistics and Economic Studies (www.insee.fr) and the European (ASR-E), Segi World (ASR-W), and the US (ASR-US) standard populations. The analyses presented here describe the overall ASR and the ASR by sex. Age-specific incidence rates are provided by age groups (0--14; 15--24; 25--39; 40--64; 65--74 and 75 and more) and by sex and presented in figures.

Time trends were calculated using Joinpoint Trend Analysis Software setting a maximum of a single Joinpoint (details in online supplementary material). The annual percent change (APC) with the 95% confidence interval (CI) was estimated according to topographic and histologic groups.

Results {#Sec6}
=======

Over the 2010--13 period, sarcomas accounted for 1.3% (3942/307,862) of all malignant tumors diagnosed over the French registry area. The male/female ratio for overall sarcomas was 1.0 but ranged from 0.5 for angiosarcomas to 6.2 for Kaposi sarcomas (KS) (Table [1](#Tab1){ref-type="table"}). The median age was 63 years (range: 0--106) with large intergroup variations. About 9% of subjects were under 24 years and 27% were older than 75 years. Almost half of the cases were soft tissue sarcomas (45%). The most frequent histological subtypes were undifferentiated or unclassified sarcomas (16%), leiomyosarcoma (14%) and GIST (13%). Sarcomas with complex genomics accounted for the most frequent molecular profile (40%). Table 1Gender distribution of sarcoma patients according to age and topographic, genomic and histologic groups. FRANCIM network data 2010--2013 (19 registries)***Male**Female**Overall**Sex ratio***\
***M/F**n**%**n**%**n**%*Age group (in years)** 0--14814.1814.11624.11.0 15--24995.0794.01784.51.3 25--3919710.01608.13579.11.2 40--6467134.173837.4140935.70.9 65--7437619.137919.275519.21.0 75 and more54627.753527.1108127.41.0**Sarcoma topographic groups** Soft tissue97249.381241.2178445.31.2 Bone31015.725913.156914.41.2 Skin26213.31678.542910.91.6 Viscera  Gastro-intestinal organs29114.828714.657814.71.0  Female genital organs----28214.32827.2--  Others visceral organs1025.21296.52315.90.8 Other anatomic sites331.7361.8691.80.9**Sarcoma genomic groups** Complex genomic alterations72336.684743.0157039.80.9*MDM2* amplification1356.9814.12165.51.7 Mutations27413.927614.055014.01.0 Recurrent translocations34017.343822.277819.70.8 Undefined/Miscellaneous alterations49825.333016.782821.01.5**Sarcoma histologic groups** Unclassified sarcoma^a^32716.630815.663516.11.1 Leiomyosarcoma20510.434617.555114.00.6 GIST24612.525012.749612.61.0 Liposarcoma22811.61306.63589.11.8*Dedifferentiated liposarcoma1256.3693.51944.91.8Round cell \\ Myxoid liposarcoma422.1291.5711.81.4Pleomorphic liposarcoma180.970.4250.62.6Liposarcoma NOS432.2251.3681.71.7* Chondrosarcoma1236.21186.02416.11.0 Dermatofibrosarcoma1015.11246.32255.70.8 Kaposi sarcoma1567.9251.31814.66.2 Angiosarcoma542.71155.81694.30.5 Osteosarcoma844.3713.61553.91.2 Ewing sarcoma723.7653.31373.51.1 Myxofibrosarcoma753.8492.51243.11.5 Rhabdomyosarcoma663.4512.61173.01.3*Embryonal rhabdomyosarcoma271.4160.8431.11.7Alveolar rhabdomyosarcoma100.5120.6220.60.8Pleomorphic rhabdomyosarcoma140.770.4210.52.0Spindle cell rhabdomyosarcoma70.470.4140.41.0Rhabdomyosarcoma NOS80.490.5170.40.9* Nerve Sheath Tumors381.9442.2822.10.9 Endometrial stromal sarcoma----814.1812.1-- Synovial sarcoma371.9402.0772.00.9*Spindle cell synovial sarcoma191.0201.0391.01.0Biphasic synovial sarcoma30.170.3100.20.4Synovial sarcoma NOS150.8130.7280.71.2* Chordoma402.0271.4671.71.5 Solitary fibrous tumor, malignant331.7331.7661.71.0 Fibrosarcoma150.8160.8310.80.9 Malignant myoepithelioma120.6110.6230.61.1 Epithelioid haemangioendothelioma90.5110.6200.50.8 Other (with fewer than 20 cases)492.5572.91062.70.7**Overall**1970100.01972100.03942100.01.0^a^Unclassified sarcomas include: Sarcoma NOS (ICDO-88003), undifferentiated spindle cell sarcoma (ICDO-88013), undifferentiated pleomorphic sarcoma (ICDO-88023), undifferentiated round cell sarcoma (ICDO-88033), epithelioid sarcoma (ICDO-88043), undifferentiated sarcoma NOS (ICDO-88053)

The crude incidence rate and ASR-W of sarcomas were 7.4 and 5.0, respectively (Table [2](#Tab2){ref-type="table"}). The ASR-W of soft tissue, bone and gastro-intestinal sarcomas were 2.1, 1.0 and 0.6, respectively. For the five most frequent histological subtypes, the ASR-W ranged from 0.3 to 0.7 with gender variations. For the two most frequent genomic profiles (over 60% of all sarcoma cases) the ASR-W was 1.9 for complex genomic and 1.3 for recurrent translocation events. Table 2Sarcoma crude and age-standardized incidence rate per 100,000 person-years according to topographic, genomic and histological groups by sex. FRANCIM network data 2010--2013 (19 registries)Median AgeMaleFemaleOverallCIRASR-W (segi)ASR-EASR-USCIRASR-W (segi)ASR-EASR-USCIRASR-W (segi)ASR-EASR-US**Sarcomas by topographic groups** Soft tissue653.702.433.123.312.901.912.342.383.302.152.682.78 Bone471.201.091.161.170.900.850.870.881.100.961.011.01 Skin541.000.700.880.910.600.460.540.540.800.590.720.73 Viscera  Gastro-intestinal organs691.100.650.910.951.000.570.770.791.100.580.810.84  Female genital organs62--------1.000.620.820.811.000.620.820.81  Other visceral organs650.400.260.330.330.500.280.360.370.400.260.340.35  Others anatomic sites550.100.150.130.130.100.100.100.100.100.100.100.10**Sarcomas by genomic groups** Complex genomic alterations652.801.782.302.433.101.932.442.472.901.872.382.45*MDM2* amplification680.500.300.420.450.300.180.230.230.400.230.310.33 Mutations681.100.660.870.901.000.580.760.771.000.620.800.83 Recurrent translocations461.301.231.301.301.601.441.561.541.501.341.441.43 Undefined/Miscellaneous alterations651.901.271.621.701.200.730.900.941.600.971.221.26**Sarcomas by histologic groups** Unclassified sarcoma^a^691.300.711.001.081.100.620.820.851.200.650.900.94 Leiomyosarcoma660.800.430.620.681.300.740.990.991.000.580.790.81 GIST690.900.520.750.780.900.470.650.670.900.500.700.72 Liposarcoma670.900.480.680.720.500.280.370.370.700.380.510.53*Dedifferentiated liposarcoma690.500.240.350.380.300.110.160.160.400.170.250.26Round cell \\ Myxoid liposarcoma510.200.130.160.160.100.090.110.110.100.100.120.12Pleomorphic liposarcoma730.100.030.040.050.000.000.000.000.000.010.020.02Liposarcoma, NOS670.200.090.130.140.100.040.050.060.100.050.080.08* Chondrosarcoma550.500.320.410.400.400.300.360.360.500.340.410.41 Dermatofibrosarcoma440.400.310.350.350.500.400.450.440.400.370.420.41 Kaposi sarcoma630.600.400.520.540.100.040.060.060.300.200.270.28 Angiosarcoma730.200.100.150.160.400.170.250.270.300.160.230.25 Osteosarcoma340.300.340.330.330.300.250.240.250.300.280.270.27 Ewing sarcoma190.300.350.300.300.200.320.270.270.300.330.280.28 Myxofibrosarcoma660.300.160.220.220.200.100.140.140.200.140.190.19 Rhabdomyosarcoma250.300.260.240.250.200.210.180.180.200.250.220.23*Embryonal rhabdomyosarcoma120.100.150.110.110.100.090.060.060.100.110.080.08Alveolar rhabdomyosarcoma220.000.050.040.040.000.080.060.060.000.050.040.04Pleomorphic rhabdomyosarcoma690.100.020.030.030.000.010.010.010.000.010.020.02Spindle cell rhabdomyosarcoma400.000.000.000.010.000.030.020.020.000.000.000.00Rhabdomyosarcoma NOS640.000.010.010.010.000.010.020.020.000.010.020.02* Nerve Sheath Tumors550.100.100.130.130.200.120.150.150.200.120.150.15 Endometrial stromal sarcoma62--------0.300.170.230.230.300.170.230.23 Synovial sarcoma470.100.160.170.170.100.130.150.140.100.150.160.16*Spindle cell synovial sarcoma490.10.070.050.050.100.050.060.060.100.050.070.07Biphasic synovial sarcoma440.00.000.000.000.000.020.010.010.000.000.000.00Synovial sarcoma NOS440.10.060.040.060.000.050.050.050.100.050.050.05* Chordoma610.200.110.140.150.100.060.080.080.100.090.120.12 Solitary fibrous tumor. Malignant630.100.110.140.130.100.080.100.100.100.100.120.12 Fibrosarcoma600.100.030.050.050.100.030.040.040.100.030.040.04 Malignant myoepithelioma560.000.030.040.040.000.030.040.040.000.030.040.04 Epithelioid haemangioendothelioma470.000.030.030.030.000.050.050.050.000.050.060.06 Other (with fewer than 20 cases)460.200.190.170.180.200.190.200.200.200.200.200.20**Total**637.605.276.546.807.204.815.835.907.405.006.126.26*Abreviations*: *GIST* Gastro-Intestinal Stromal Tumors, *CIR* Crude Incidence Rate per 100,000 persons-years, *ASR-W*, *ASR-E* and *ASR-US* Age-Standardized incidence Rate from three reference populations (W, World Segi; E, European; US, United-States)^a^Unclassified sarcomas include: Sarcoma not otherwise specified (ICDO-88003), undifferentiated spindle cell sarcoma (ICDO-88013), undifferentiated pleomorphic sarcoma (ICDO-88023), undifferentiated round cell sarcoma (ICDO-88033), epithelioid sarcoma (ICDO-88043), undifferentiated sarcoma NOS (ICDO-88053)

The overall sarcoma incidence peaked at 22 in patients aged 75 or over (data not shown). Age-specific rates for soft tissue, viscera and skin sarcomas were relatively stable among patients aged between 0 and 40 years, and then increased with age (Fig. [1](#Fig1){ref-type="fig"}). This increase was less pronounced in women. In men, bone sarcomas presented a biphasic profile with a first peak in young people between 15 and 25 years of age and a second peak in adults aged between 65 and 74 years of age. With respect to histological subtypes, age-specific incidence rates had various profiles (see Additional File [2](#MOESM2){ref-type="media"}). According to the genomic profile, the incidence increased steadily with age, except for tumors harboring recurrent translocations and *MDM2* amplification among women (see Additional File [3](#MOESM3){ref-type="media"}). Fig. 1Age-specific incidence rates of sarcomas per 100,000 person-years according to topographic groups. FRANCIM network data 2010--2013 (19 registries)

The ASR-W for all sarcomas increased between 2000 and 2005 (APC = 3.6%), and remained stable since 2005 (non-significant APC, Table [3](#Tab3){ref-type="table"}). According to the anatomic site, the ASR-W decreased for skin sarcomas (APC = -2.0%) and female genital tumors between 2005 and 2013 (APC = -2.2%). Stratifying by major histological subtypes, the ASR-W increased for GIST (APC = 3.7%), chondrosarcoma (APC = 4.1%), myxofibrosarcoma (8.2%) and solitary fibrous tumors (12.2%) and decreased for leiomyosarcoma (APC = -2.6%), Kaposi sarcoma (− 4.1%) and fibrosarcoma (APC = -9.2%). All trend figures are provided in the online supplementary material (see Additional Files [4](#MOESM4){ref-type="media"} and [5](#MOESM5){ref-type="media"}). Table 3Annual percentage change of world age-standardized incidence rate by topographic groups, histologic types. FRANCIM network data 2000--2013 (11 registries)nJoinpointAPC95% CI**Sarcomas by topographic groups** Soft Tissue37660.8(−0.4; 2.0) Bone11931.2(−0.4; 2.9) Skin1062**-2.0**^*a*^(−3.5; −0.4) Viscera tumors organs  Gastro-intestinal organs10531.5(−0.3; 3.3)  Female genital organs2972000--20054.2(−4.2; 13.2)3762005--2013**−6.7**^*a*^(−10.4; −2.7)  Other visceral organs540−1.7(−5.1; 1.8)  Other anatomic sites1711.0(−3.4; 5.6)**Sarcomas by histologic groups** Unclassified sarcoma1513−1.6(−3.6; 0.3) Leiomyosarcoma1281**−2.6**^*a*^(−4.6; −0.6) GIST822**3.7**^*a*^(0.8; 6.8) Liposarcoma7131.3(−1.1; 3.7) Dermatofibrosarcoma4960.6(−1.4; 2.7) Chondrosarcoma454**4.1**^*a*^(1.6; 6.6) Kaposi sarcoma419**−4.1**^*a*^(−6.8; −1.4) Osteosarcoma359−0.6(−3.7; 2.6) Angiosarcoma3352.2(−1.2; 5.7) Ewing sarcoma330−0.2(−4.1; 3.8) Rhabdomyosarcoma286−1.1(−6.2; 4.4) Others (with fewer than 20 cases)2264.1(−1.3; 9.8) Synovial sarcoma2191.2(−4.2; 6.9) Nerve Sheath Tumors191−0.1(−4.3; 4.4) Myxofibrosarcoma183**8.2**^*a*^(0.4; 16.6) Endometrial stromal sarcoma173−3.7(−7.4; 0.1) Fibrosarcoma151**−9.2**^*a*^(−15.7; −2.3) Chordoma1260.8(−4.8; 6.6) Solitary fibrous tumor. Malignant102**12.2**^*a*^(6.2; 18.5) Epithelioid haemangioendothelioma55---- Myoepithelial carcinoma24----**Total**33592000--2005**3.6**^*a*^(0.2; 7.1)50992005--2013−1.4(−2.9; 0.1)Note. Joinpoint = years when statistically significant changes in incidence trend occurred*APC* Annual Percent Change, *CI* Confidence Interval^a^Indicates that the APC is significantly different from 0 at the alpha = 0.05 level

Discussion {#Sec7}
==========

In this study, we precisely described the incidence of sarcomas according to different classifications (anatomic, histologic and genetic) using data from population-based cancer registries. To our knowledge, this is one of the first reports on sarcomas based on a systematic pathological review of these cancers while taking into account the updated sarcoma classifications.

In this study, sarcomas accounted for 1.3% of all malignant tumors (1.1% for soft tissue -including skin and viscera- and 0.2% for bone) and had an ASR-E of 6.1 per 100,000 person-years over the 2010--2013 period (European population standard). The ASR-E was slightly higher than that reported in Europe \[[@CR12]\]. Data comparison between countries is difficult due to the heterogeneity of sarcoma definition used as inclusion criteria. This heterogeneity is mainly related to some analysis characteristics: i) certain specific histological subtypes are not consistently included in analyses (e.g. Kaposi sarcoma or dermatofibroma sarcoma); ii) some studies consider adults and children separately, while others mix them; and iii) anatomic sites may be limited to specific sites such as STS. The current approach to describe sarcomas using registry data based on expert recommendations are expected to better follow epidemiological indicators and to carry out reliable comparisons between countries.

With respect to the anatomic site, ASR-E for STS (2.7) in our study was below most published international incidence rates. This may be explained by the exclusion of visceral sarcomas of soft tissue and the different description of well-differentiated liposarcoma compared to the WHO 2013 classification. In the current study, ASR-Ws for bone sarcomas among males and females (1.1 and 0.9 respectively) were close to those recently reported in five continents (2010--13 period, ASR-W 0.8--1.2 in males and 0.5--1.0 in females) \[[@CR13]\]. For visceral sarcomas, the comparison between studies with inclusion periods close to that in the present study showed ASR-E similar to ours \[[@CR8], [@CR14]\]. In contrast, the ASR was greater than that reported in the RARECARE project, which may be due to differences in the definition of visceral sarcomas (GIST not included) \[[@CR14]\].

The comparison of ASRs for main histologic groups between studies with a shorter inclusion period showed that the ASR-E for leiomyosarcoma (0.8; 0.6 for males and 1.0 for females) was greater than that reported in France (0.6) and was similar to that reported in three European regions (0.5 for males and 1.0 for females) \[[@CR8], [@CR14]\]. ASR-E for liposarcoma in our study (0.5; 0.7 for males and 0.4 for females), was lower than that reported in France (0.8) and in three European regions (1.06 for males and 0.59 for females), which may be attributed to differences in the definition of liposarcoma as inclusion criteria \[[@CR8], [@CR14]\]. In our study, we found an ASR-W for osteosarcoma slightly lower than that of chondrosarcoma (0.28 versus 0.34). For male, ASR-W was equivalent (0.34 versus 0.32). A recent population-based study from Swiss cancer registries showed similar results \[[@CR15]\]. In contrast, others studies based on older inclusion period of sarcoma diagnosis found an ASR-W slightly higher for osteosarcoma \[[@CR8], [@CR16]\]. However, looking at the trend in our study (Additional File [5](#MOESM5){ref-type="media"}), we can notice that the ASR-W of osteosarcoma was actually higher over the period 2000--2005 than the ASR-W of chondrosarcoma in accordance with these studies. The increasing trend in the ASR of chondrosarcoma and the stabilization of the ASR of osteosarcomas may logically explain why the incidence of chondrosarcomas has been higher than that of osteosarcomas in recent years.

Molecular biology of sarcomas, available for diagnosis in France since 2010 is a complementary approach and has led to a molecular classification for sarcomas \[[@CR17]\]. For the first time, we provided ASR at national level and showed molecular profiles by age groups.

This study provides the first time trend analysis of sarcomas in France and shows that ASR-W for sarcomas increased between 2000 and 2005 (APC = 3.6%) and stabilized from 2005. The current study has not shown an increase in ASR-W for soft-tissue sarcomas. This is in contrast to reports in others countries covering different periods: in the United States APC was 1.2% for males and 0.8% for females between 1978 and 2001, in Japan APC was 0.6% between 1978 and 2007 and in Serbia APC was 0.77% between 1985 and 2009 \[[@CR18]--[@CR20]\]. We report a significant decrease in incidence for skin sarcomas over the study period and for female genital sarcomas since 2005. Some histological subtypes have shown a significant decrease over the study period: leiomyosarcoma, KS and fibrosarcoma. The decline for KS has also been described in the population from the United States over the same period \[[@CR21]\]. These changes are consistent with the improvement in access for antiretroviral therapy among HIV-infected patients and the declining AIDS incidence in developed countries. The decrease in incidence of leiomyosarcoma and fibrosarcoma could be explained by a histological classification published by the WHO in 2002 that includes new data of immunohistochemistry and new histological subtypes. Similarly, we report an increase in incidence of GIST, likely related to the introduction in the early 2000s of an immunohistochemical diagnostic test specific to GIST tumors (*KIT*-activating mutations). Further, the increase in GIST was more noticeable before 2005 and stabilised after 2005. The time trend analysis also revealed a significant increase for chondrogenic sarcomas (APC = 4.4%). Such increase has been reported in a study from the United States including only women (1976--2005) \[[@CR20]\], whereas a study from the United Kingdom showed the same trend in incidence for both sexes (1988--2007) \[[@CR13]\]. The strongest hypothesis to explain the increased risk of chondrogenic sarcoma in women is the introduction of exogenous estrogen exposures (oral contraceptives, hormone therapy), whereas other factors has to be identified in men \[[@CR13], [@CR16]\].

The different incidence trends for sarcomas reported over the world may partly be explained by variations in diagnosis practices and the classification used. The impact of environmental factors in the etiology of these cancers may also be a point at issue. However, the large heterogeneity of histological subtypes and the rarity of sarcomas prevent examining this association and drawing conclusions from existing environmental epidemiological studies. A national French study on the etiology of sarcomas (Etiosarc) has been launched to study the possible effect of environmental factors \[[@CR22]\].

A major strength in this study is that the incidence of sarcomas was estimated using the 2013 WHO classification \[[@CR1]\]. Whenever possible, registry data was converted to the latest classification to take into account changes and evolutions between different classifications (e.g. new morphological terms, obsolete morphological codes and terms).

Moreover, this study is the first to describe sarcomas in a geographic area where an expert sarcoma pathologist reviews the pathologic diagnosis. Contrary to imperfectly estimated sarcoma incidence rates, this review allows to provide a consistent incidence of sarcomas. A French study, confirmed these results and indicated that 45% of sarcomas are misclassified at initial diagnosis and that 19% have complete discordance \[[@CR3]\]. For this reason, the review for sarcoma diagnosis is necessary to estimate a consistent incidence and more so for the different subgroups. In France, the second review was based on voluntary participation before the year 2010. Thereby, we cannot be certain that the review was obtained for all sarcomas in the period 2000--2010, even if significant efforts were made by French sarcoma network in order that pathologists systematically send slides of any newly diagnosed of sarcomas. For this reason, the estimated incidence over the 2010--2013 seems to be most relevant and reliable.

Conclusion {#Sec8}
==========

This study provided the opportunity to precisely describe the incidence of sarcomas according to three different groups (anatomic, histologic and genetic) defined by sarcoma specialists using data from population-based cancer registries. To our knowledge, this study is the first to report sarcoma incidence based on a systematic pathological review of these cancers and taking into account the updated sarcoma classifications. Due to literature paucity on sarcomas, future studies using data from population-based cancer registries will have to consider a strict inclusion criterion presented in our study to better describe and compare data between countries. The molecular classification will be useful for etiological studies as incidence studies.
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APC

:   Annual percentage change

ASR

:   Age-standardized incidence rates

CI

:   Confident interval

GIST

:   Gastro-intestinal stromal tumors

ICD-O-3

:   International Classification of Diseases for Oncology, third edition

KS

:   Kaposi sarcoma
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